Included in this issue:

• #NACCT2026 ACMT Pre-Symposium
• New Publications
• Total Tox Course: Registration Open
• Alnylam Fellowship: Applications Open
• September Calendar of Events

T O P    S T O R I E S

Photo (from left to right): Paul Wax, MD, DFACMT; Kim Aldy, DO, MS, MBA; Jeffrey Brent, MD, PhD, DFACMT 

ToxIC Visits FDA to Present at the Controlled Substances Rounds

In August, ToxIC leadership visited the U.S. Food and Drug Administration (FDA) to present at the FDA Controlled Substances Rounds. The team presented findings from the ongoing Real-world Examination of Naloxone for Drug Overdose Reversal (RENDOR) study, highlighting bystander and pre-EMS naloxone administration in the prehospital setting.

The visit provided an opportunity to demonstrate the value of medical toxicology expertise in generating real-world evidence to better understand prehospital naloxone use, inform overdose treatment, and improve approaches to optimizing care for patients experiencing opioid overdose.

In the coming year, RENDOR will expand its scope to include analysis of residual blood specimens from a subset of patients transported to participating hospitals. In collaboration with the Center for Forensic Science Research and Education (CFSRE), the specimens will be tested for emerging drugs, providing insight into the evolving illicit drug supply and helping assess naloxone’s effectiveness in overdoses involving these substances. 

N E W    P U B L I C A T I O N S

ACMT Position Statement: What Is a Medical Toxicologist?

As medical toxicology continues to grow and intersect with many other disciplines, the terminology used to describe toxicology professionals is often misunderstood or used interchangeably. To address this, the ACMT Position Statements Committee developed a new What Is a Medical Toxicologist? statement, which has been approved by the ACMT Board of Directors.

The statement establishes ACMT's official definition of a medical toxicologist, clearly distinguishing the specialty from other toxicology specialists.

Read Full Statement

ACMT Position Statement: Public Health Concerns Associated with 7-Hydroxymitragynine and Other Kratom Compounds

Seven-hydroxymitragynine (7-OH) and other compounds from kratom have been shown in animal studies to function as opioids. Clinical experience indicates that 7-OH is associated with opioid-like effects, including intoxication, respiratory depression, dependence, and withdrawal. Although 7-OH occurs naturally only in trace amounts in the kratom leaf, commercially available products containing concentrated 7-OH have been linked to overdose and death. Cases of 7-OH withdrawal and dependence have been successfully treated using medications for opioid use disorder such as buprenorphine or methadone. At present, there are no proven therapeutic benefits for 7-OH and other kratom-associated compounds. Additional clinical research is needed to better define their pharmacology, safety profile, and potential therapeutic applications. Use of 7-OH should occur in the context of clinical research conducted with appropriate institutional, regulatory, and ethical oversight. ACMT supports measures to prevent the unrestricted, nonprescription sale of opioid agonists.

Read Full Statement

ACEP Unscheduled Procedural Sedation Guidelines Published

American College of Emergency Physicians (ACEP) Unscheduled Procedural Sedation Guidelines, part 1 and 2, were just published in the September issue of Annals of Emergency Medicine. Read through and familiarize yourself with these important guidelines below:

Part 1    |   Part 2

M E M B E R    O P P O R T U N I T I E S

ANTIDOTE Institute: Research & Career Development Opportunities

Applications Due: November 6th, 2026

The ANTIDOTE Institute, supported by the American College of Medical Toxicology (ACMT) and National Institute on Drug Abuse (NIDA), provides mentorship, research funding, grant development, and career guidance for medical toxicologists pursuing careers in research related to addiction, substance use, and health outcomes.

FIT Program: For first- and second-year fellows interested in translational research. This one-year mentored experience provides exposure to ANTIDOTE and includes a travel award to attend one in-person retreat held with ACMT’s Annual Scientific Meeting.

Full Program: A two-year program for junior faculty within five years of fellowship graduation at a U.S.-based institution. Participants receive mentorship, research and grant development support, and travel awards to attend three ANTIDOTE retreats.

Alumni Supplemental Award: Available to current or past ANTIDOTE participants who are ACMT members in good standing and hold an appointment at a U.S.-based institution.

Learn More & Apply

Travel Awards Available for Medical Students, Residents & Future Medical Toxicologists

Apply by October 12, 2026, and submit one application to be considered for all eligible awards. 

Are you a medical student, resident, or trainee interested in medical toxicology? The Medical Toxicology Foundation (MTF) is offering several travel awards to help support attendance at the ACMT Annual Scientific Meeting. These awards provide a unique opportunity to connect with leaders in the specialty, explore groundbreaking research and clinical advancements, and learn more about a future in medical toxicology.

Applications are now open for the Dr. Carol R. Angle Pediatric Toxicology Travel Award, Resident Travel Award, Dr. Michael Shannon Travel Award, and Johnson & Johnson Consumer Health Travel Award.

Learn More & Apply

Alnylam Safety and Risk Management Physician Fellowship

Submission Deadline: September 30th, 2026

The Alnylam Safety & Risk Management (GPSRM) Physician Fellowship offers medical toxicologists a unique opportunity to gain hands-on experience in the biopharmaceutical industry while developing expertise in pharmacovigilance, drug safety, and risk management.

This one-year, full-time fellowship places participants on Alnylam's Global Patient Safety & Risk Management team, where they work alongside industry leaders to help monitor, evaluate, and communicate the safety of innovative RNAi therapeutics throughout the drug development lifecycle.

Learn More & Apply

The Charles E. Becker Medal: Accepting Applications

Submission Deadline: November 16, 2026

The Charles E. Becker Medal for Outstanding Achievement as a Medical Toxicology Fellow was established with the generous support of Dr. Charles Becker, a pioneering leader in establishing the specialty of medical toxicology. This award aims to recognize an outstanding fellow who embodies the humanitarian spirit of Dr. Becker and whose professional goals include a desire to make a significant contribution to advance the field of medical toxicology. In addition to accepting the medal, the recipient will receive registration to the Annual Scientific Meeting and $1,500 monetary award, which may be used towards travel expenses.

Eligible applicants are those individuals who have recently (within the past 2 years) completed a US ACGME accredited two year fellowship in Medical Toxicology.

Learn More & Apply

U P C O M I N G    E V E N T S

S E P T E M B E R    C A L E N D A R

Have something to share? We would love to hear from you!

Whether its a new promotion, a publication, or a neat tox project you're working on, ACMT would love to hear about what our members are up to. Send us an email at communications@acmt.net and we may include your story in an upcoming newsletter!